First Progress Meeting for the 3TR Project: One Year Completed, Six Years Ahead

From 2-3 October 2020, the 3TR consortium gathered virtually for its first progress meeting. More than 220 participants came together to discuss the progress of the project one year after its kick-off. Even though the consortium was not able to meet in person due to the COVID-19 pandemic, the meeting was still a great opportunity for the 69 academic and industrial partners to provide each other with more detailed feedback on this flagship project.

On the first meeting day, the Project Coordinator, Marta Alarcón Riquelme (FPS), and the Project Leader, Terry Means (Sanofi), were setting the stage and had the privilege of welcoming the science, ethics and patient advisors as well as the project’s scientific officer from IMI, Isabella Tamagnini. The rest of the day was filled with presentations from work package leaders and co-leaders as well as from different disease-focused working groups. The groups gave an update on their work, presented achievements and addressed challenges as well as upcoming activities. The second meeting day focused more on trans-disease activities: Apart from scientific activities, the engagement of regulatory bodies, including aspects such as patient-reported outcomes, were discussed.

At the end of the meeting, Marta Alarcón Riquelme (FPS) concluded: “We can look back on a very successful project start and an exciting and strongly collaborative first year. Of course, the COVID-19 pandemic has presented a huge challenge for many partners over the last months. Nevertheless, we are now well underway to achieve our goal of identifying molecular signatures for non-response to treatments and therefore increasing the knowledge of the molecular pathways and mechanisms within and across these immune-mediated diseases. We have to keep up the excellent work to the benefit of our most important stakeholders – the patients. I am looking forward to exciting six more years in the 3TR project.” And Terry Means (Sanofi) stated that “it is great to see the progress our project has made within the first year; 3TR now has a strong collaborative foundation, for example the design of the different clinical studies is close to being finalised. The discussions, though just virtual, were valuable and helped to identify new points of action to reach our project goal.”

For further information and a full 3TR partner list, please visit 3tr-imi.eu. You can also follow 3TR on Twitter: @3TR_IMI

The Eurice team is involved in 3TR as a management and communication partner and contributes to the successful implementation of the project goals by supporting the consortium in all aspects of project management and the communication activities.